This site is intended for healthcare professionals
Live Webinar - Registration

Integrating anti-TNF biosimilars into management of rheumatoid arthritis: when and how?

Read time: 5 mins
Last updated:28th Jun 2022
Published:28th Jun 2022

Live: Thursday 1st September 2022 | 15:30–16:00 CEST

While some key benefits of biosimilars were outlined in the first Webinar of this series, realising these benefits relies upon their successful integration into clinical practice. However, some questions remain - when might they be considered for patients, and what factors influence their use in practice? Register for our live webinar to learn more about the practical considerations for integrating anti-TNF biosimilars into management of rheumatoid arthritis (RA).

In this webinar, Professor Peter Taylor and Professor Josef Smolen provide expert insights on where anti-TNF biosimilars fit into clinical management of RA.

  • Explore scenarios where anti-TNF biosimilars may be considered for patients with RA, and when switching from a reference biologic or biosimilar may be appropriate
  • Listen to an expert discussion on the practical aspects of integrating anti-TNF biosimilars into clinical management of RA, and key challenges in practice

Webinar Agenda

  Integrating anti-TNF biosimilars into management of rheumatoid arthritis: when and how?
Thursday 1 September 2022 | 15:30–16:00 CEST
  Chair: Professor Peter Taylor
15:30 Welcome, introductions and overview Professor Peter Taylor
15:32 Where do anti-TNF biosimilars fit into management of rheumatoid arthritis? Professor Josef Smolen
15:47 Practical considerations for integrating anti-TNF biosimilars into management of rheumatoid arthritis Faculty discussion
15:59 Closing remarks Professor Peter Taylor

Gain valuable insights and expert perspectives on where and how anti-TNF biosimilars fit into management of rheumatoid arthritis

What’s the purpose of this webinar?

The aim of this webinar event is to provide healthcare professionals with expert insights into how anti-TNF biosimilars fit into the management of RA. In this second webinar in a 3-part series, our expert faculty describe the utility of anti-TNF biosimilars and their role in management of RA, and provide insights on the practicalities of integrating anti-TNF biosimilars into RA management, including strategies for biosimilar switching and cycling.

Missed the first webinar? You can watch the first webinar in this series, on ‘Anti-TNF biosimilars for rheumatic diseases: the key to early treatment?’ via the link below.

Watch webinar one

Faculty

Professor Peter Taylor.jpg

Professor Peter Taylor

Professor Peter C. Taylor trained at Cambridge and Oxford Universities and gained a PhD from the University of London. He holds the Norman Collisson chair of musculoskeletal sciences at Oxford University where he is the Director of Clinical Sciences at the Botnar Research Centre. Professor Taylor has over thirty years of experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis including the earliest seminal trails of anti-TNF and anti-IL-6 receptor therapy. He has specialist clinical interests in novel therapies, rheumatoid and early arthritis.

Financial disclosures: Professor Taylor has declared research grants from Celgene, Galapagos; and consultation fees from AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Lilly, Pfizer, Roche, Sanofi, Nordic Pharma, Fresenius and UCB.

Professor Christopher Edwards.jpg

Professor Josef Smolen

Josef Smolen is Emeritus Professor of Medicine at the Medical University of Vienna, Austria. He received his MD degree from the University of Vienna, trained there in Immunology, Medicine and Rheumatology and was research fellow at the Arthritis Institute at the National Institutes of Health, Bethesda, MD, USA. 1989-2017 he was Chairman of 2nd Department of Medicine at Hietzing Hospital and 1995-2018 Professor of Medicine and Chairman of the Division of Rheumatology at Medical University of Vienna, where he also acted as Chairman of the Department of Medicine 3 from 2007-2018.

Financial disclosures: Professor Smolen has declared research grants from Abbvie, AstraZeneca, Lilly, Novartis and Roche; and consultation fees from AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, Merck Sharp & Dohme, Novartis- Sandoz, Pfizer, R-Pharm, Roche, Samsung, Sanofi, and UCB.

Welcome:

Developed by EPG Health for Medthority. This content has been developed independently of the sponsor, Sandoz, who has had no editorial input into the content. Medthority received unrestricted educational grant funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information and associated relevant content, without any promotional intent. This content is intended for healthcare professionals only.